Log In
BCIQ
Print this Print this
 

Biosimilar rituximab (JHL1101)

  Manage Alerts
Collapse Summary General Information
Company JHL Biotech Inc.
DescriptionBiosimilar rituximab, a chimeric mAb against CD20 antigen
Molecular Target CD20
Mechanism of ActionBinds CD20; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today